Type I Interferon Responses Drive Intrahepatic T cells to Promote Metabolic Syndrome
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Magar Ghazarian, Xavier S Revelo, Mark K Nøhr, Helen Luck, Kejing Zeng, Helena Lei, Sue Tsai, Stephanie A Schroer, Yoo Jin Park, Melissa Hui Yen Chng, Lei Shen, June Ann D'Angelo, Peter Horton, William C Chapman, Diane Brockmeier, Minna Woo, Edgar G Engleman, Oyedele Adeyi, Naoto Hirano, Tianru Jin & 3 andre
Obesity-related insulin resistance is driven by low-grade chronic inflammation of metabolic tissues. In the liver, non-alcoholic fatty liver disease (NAFLD) is associated with hepatic insulin resistance and systemic glucose dysregulation. However, the immunological factors supporting these processes are poorly understood. We found that the liver accumulates pathogenic CD8+ T cell subsets which control hepatic insulin sensitivity and gluconeogenesis during diet-induced obesity in mice. In a cohort of human patients, CD8+ T cells represent a dominant intrahepatic immune cell population which links to glucose dysregulation. Accumulation and activation of these cells are largely supported by type I interferon (IFN-I) responses in the liver. Livers from obese mice upregulate critical interferon regulatory factors (IRFs), interferon stimulatory genes (ISGs), and IFNα protein, while IFNαR1-/- mice, or CD8-specific IFNαR1-/- chimeric mice are protected from disease. IFNαR1 inhibitors improve metabolic parameters in mice, while CD8+ T cells and IFN-I responses correlate with NAFLD activity in human patients. Thus, IFN-I responses represent a central immunological axis that governs intrahepatic T cell pathogenicity during metabolic disease.
|Bogserie||Advances in Immunology|
|Status||Udgivet - 21 apr. 2017|